Kalaris Therapeutics Inc stock is traded at $2.61, with a volume of 144,235. It is up +10.59% in the last 24 hours and down -1.88% over the past month. Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Previous Close:
$2.36
Open:
$2.36
24h Volume:
144,235
Relative Volume:
2.74
Market Cap:
$62.13M
Revenue:
-
Net Income/Loss:
-$44.10M
P/E Ratio:
-
EPS:
-$2.14
Net Cash Flow:
-$49.09M
1W Performance:
+28.57%
1M Performance:
-1.88%
6M Performance:
-48.42%
1Y Performance:
-44.82%
1-Day Range:
$2.34$2.66
1-Week Range:
$1.92$2.66
52-Week Range:
$1.78$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
650-249-2727Address
400 CONNELL DRIVE, BERKELEY HEIGHTS, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS